Karen Fusaro - Seelos Therapeutics Senior Operations
Executive
Karen Fusaro is Senior Operations of Seelos Therapeutics
| Phone | 646 293 2100 |
| Web | https://seelostherapeutics.com |
Seelos Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.6111) % which means that it has lost $2.6111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.842) %, meaning that it created substantial loss on money invested by shareholders. Seelos Therapeutics' management efficiency ratios could be used to measure how well Seelos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Seelos Therapeutics currently holds 14.23 M in liabilities with Debt to Equity (D/E) ratio of 0.73, which is about average as compared to similar companies. Seelos Therapeutics has a current ratio of 3.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seelos Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Seelos Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seelos Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seelos to invest in growth at high rates of return. When we think about Seelos Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Julie FCA | GH Research PLC | 38 | |
| David JD | Pulmatrix | 66 | |
| Frank Stegert | ATAI Life Sciences | 44 | |
| Philippe Brantegem | Iteos Therapeutics | N/A | |
| Jesse Schumaker | Soleno Therapeutics | N/A | |
| Mike Campbell | Opthea | N/A | |
| Stephen Bardin | ATAI Life Sciences | 33 | |
| Meredith MBA | Soleno Therapeutics | 52 | |
| Peter MBA | Opthea | 52 | |
| Justin CPA | Tempest Therapeutics | 37 | |
| Deborah Ascheim | Capricor Therapeutics | 59 | |
| John JD | Edgewise Therapeutics | 61 | |
| Sahil MD | ATAI Life Sciences | 39 | |
| Anand Sundaram | Opthea | N/A | |
| Stephanie Fagan | Mind Medicine | N/A | |
| Pamela Trail | Molecular Partners AG | 69 | |
| Glenn Short | ATAI Life Sciences | N/A | |
| BethAnne Lang | Akari Therapeutics PLC | N/A | |
| Gregory Burshtein | Entera Bio | 49 | |
| PharmD MBA | Soleno Therapeutics | N/A | |
| Fang Li | Opthea | 61 | |
Management Performance
| Return On Equity | -5.84 | |||
| Return On Asset | -2.61 |
Seelos Therapeutics Leadership Team
Elected by the shareholders, the Seelos Therapeutics' board of directors comprises two types of representatives: Seelos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seelos. The board's role is to monitor Seelos Therapeutics' management team and ensure that shareholders' interests are well served. Seelos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seelos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gopal Krishna, Head Operations | ||
| Michael Golembiewski, Chief Officer | ||
| Kimberly Farrand, Senior Operations | ||
| Raj JD, Chairman, Founder | ||
| Anthony Marciano, Chief Officer | ||
| Karen Fusaro, Senior Operations | ||
| Tim MD, Chief Officer |
Seelos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Seelos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.84 | |||
| Return On Asset | -2.61 | |||
| Profit Margin | 2.03 % | |||
| Operating Margin | (8.35) % | |||
| Current Valuation | 10.45 M | |||
| Shares Outstanding | 581 K | |||
| Shares Owned By Insiders | 0.49 % | |||
| Shares Owned By Institutions | 4.46 % | |||
| Number Of Shares Shorted | 170.89 K | |||
| Price To Book | 15.10 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in income. Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Seelos OTC Stock
If you are still planning to invest in Seelos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seelos Therapeutics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |